BackJazz Pharmaceuticals plc Overview
Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Target Price

Analysts' average 12-month price target for Jazz Pharmaceuticals plc is $290.

Get informed when a big investor buys or sells

+ Follow

Share Price

$235.67

Average Target Price

$289.4622.8% upside

28 analysts in the last 4 months

High: $337 | Low: $254

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-24Goldman Sachs$33743% upsideOpen
2026-09-11UBS$33743% upsideOpen
2026-09-10Barclays$27115% upsideOpen
2026-08-28RBC CapitalLeonid Timashev$29926.9% upsideOpen
2026-08-26Deutsche BankDavid Hoang$30027.3% upsideOpen
2026-08-26RBC CapitalLeonid Timashev$27717.5% upsideOpen
2026-08-26Truist FinancialGregory Renza$28119.2% upsideOpen
2026-08-26Morgan Stanley$32236.6% upsideOpen
2026-08-26Needham$31031.5% upsideOpen
2026-08-26Canaccord GenuityGary Newman$30027.3% upsideOpen
2026-08-11Morgan Stanley$28320.1% upsideOpen
2026-08-04Barclays$27014.6% upsideOpen
2026-08-04Deutsche Bank$28721.8% upsideOpen
2026-08-04Truist Financial$30027.3% upsideOpen
2026-08-04Morgan Stanley$28018.8% upsideOpen
2026-08-04Truist Financial$26412% upsideOpen
2026-08-04NeedhamAmi Fadia$29223.9% upsideOpen
2026-08-04UBS$31533.7% upsideOpen
2026-08-04Wells Fargo$30027.3% upsideOpen
2026-08-04Stifel Nicolaus$27516.7% upsideOpen
2026-08-04Piper Sandler$31031.5% upsideOpen
2026-08-04Robert W. Baird$28018.8% upsideOpen
2026-07-16Canaccord GenuityGary Nachman$29023.1% upsideOpen
2026-07-14Barclays$26010.3% upsideOpen
2026-07-14Wells Fargo$28520.9% upsideOpen
2026-07-09Deutsche Bank$27014.6% upsideOpen
2026-07-07Truist FinancialGregory Renza$2547.8% upsideOpen
2026-06-09Truist FinancialGregory Renza$2568.6% upsideOpen
2026-05-27Barclays$2537.4% upsideOpen
2026-05-22Piper Sandler$30127.7% upsideOpen
2026-05-21Bernstein$2292.8% downsideOpen
2026-05-19UBSAshwani Verma$30730.3% upsideOpen
2026-05-07Morgan StanleySean Laaman$2454% upsideOpen
2026-05-06Raymond JamesTiago Fauth$2391.4% upsideOpen
2026-05-06Robert W. Baird$2526.9% upsideOpen
2026-05-06BarclaysEtzer Darout$2340.7% downsideOpen
2026-04-20BarclaysEtzer Darout$2254.5% downsideOpen
2026-04-10Raymond James$2273.7% downsideOpen
2026-03-09BarclaysEtzer Darout$2245% downsideOpen
2026-01-12NeedhamAmi Fadia$2350.3% downsideOpen
2026-01-08Morgan StanleySean Laaman$2254.5% downsideOpen
2025-12-10Piper SandlerDavid Amsellem$2197.1% downsideOpen
2025-11-24UBSAshwani Verma$18820.2% downsideOpen
2025-11-17RBC Capital$19417.7% downsideOpen
2025-11-17Morgan StanleySean Laaman$20513% downsideOpen
2025-10-24Morgan Stanley$18322.3% downsideOpen
2025-10-22Wells Fargo$17027.9% downsideOpen
2025-10-20Morgan Stanley$18023.6% downsideOpen
2025-08-28Truist FinancialJoon Lee$20513% downsideOpen
2025-08-28RBC CapitalGregory Renza$15135.9% downsideOpen

Jazz Pharmaceuticals plc (JAZZ) FAQ

Jazz Pharmaceuticals plc posts a target price of $290. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $290 for JAZZ means covering analysts, on average, see the stock 22.8% upside of $235.67 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for JAZZ's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Jazz Pharmaceuticals plc's other metric pages and overview cover the third.

Judging Jazz Pharmaceuticals plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $290 here, then scan peer and history charts to see if the gap is persistent.